Bausch targets Sandoz over IBS generic

03-10-2019

Rory O'Neill

Bausch targets Sandoz over IBS generic

Pavel Kapysh / Shutterstock.com

Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan (rifaximin), Bausch’s irritable bowel syndrome (IBS) drug.


Bausch Health, Xifaxan, IBS, irritable bowel syndrome, rifaximin, Actavis, Teva, Sandoz, Novartis, Salix Pharmaceuticals, Alfasigma

LSIPR